We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1,636.00 | 1,638.00 | 1,639.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.69 | 67.46B |
From Apr 2022 to Apr 2024
By Joe Hoppe
GSK PLC said Thursday that it will invest 1 billion pounds ($1.23 billion) to accelerate research and development over the next 10 years, targeting infectious diseases that disproportionately affect lower-income countries.
The British pharmaceutical company, formerly known as GlaxoSmithKline, said the investment will focus on new and disruptive vaccines and medicines to prevent and treat malaria, tuberculosis, HIV, neglected tropical diseases and anti-microbial resistance. These account for more than 60% of the disease burden in lower-income countries, the company said.
To deliver against its targets, GSK has formed a dedicated, non-commercial global health unit, measuring success by its effects on health alone without the concern of a commercial return on investment. This includes global health research and development hubs, which are advancing more than 30 potential new vaccines and medicines, targeting 13 high-burden infectious diseases.
Shares at 1054 GMT were up 14.4 pence, or 0.8%, at 1,720.0 pence.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
June 23, 2022 07:28 ET (11:28 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
